Health
Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF – TCTMD
Prospective studies are needed and mechanisms unclear, but the findings raise hopes for off-target benefits, says J. Emanuel Finet.
Compared with valsartan alone, the angiotensin receptor-neprilysin inhibitor (ARNI) / (Entresto; Novartis) reduces triglycerides among patients with heart failure and preserved ejection fraction (HFpEF), according to results from a PARAGON-HF subanalysis. The effect was particularly marked in patients with higher triglycerides at baseline.
Our research adds to the growing literature of the favorable metabolic effects of sacubitril/valsartan, Senthil Selvaraj, MD (Hospital of the University of Pennsylvania,…
-
Noosa News21 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General19 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
General23 hours agoMan dies at shopping centre car park at Charlestown following reports of assault
-
Noosa News23 hours agoWomen’s Softball World Cup 2027 Redcliffe Brisbane